Communiqués Halozyme Therapeutics, Inc.

Actions

HALO

US40637H1095

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
115,22 ^USD	+2,47%		+5,05%	+71,20%

18/09	Halozyme fixe le prix de son offre d'obligations convertibles de premier rang pour 1,3 milliard de dollars	MT
16/09	Halozyme Therapeutics prévoit une émission d'obligations convertibles de 1,05 milliard de dollars	MT

Communiqués

18/09	Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033	PR
02/09	Halozyme to Participate at Upcoming Investor Conferences	PR
18/08	Halozyme Appoints Dannielle Appelhans to its Board of Directors	PR
07/08	Halozyme Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Halozyme Therapeutics: Q2 Earnings Snapshot	AQ
06/08	HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE	PR
23/07	Halozyme to Report Second Quarter 2026 Financial and Operating Results	PR
21/07	Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology	AQ
20/07	Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology	PR
30/06	Halozyme Appoints David Ramsay as President Drug Delivery	PR
15/06	Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029	PR
11/05	Halozyme Therapeutics: Q1 Earnings Snapshot	AQ
11/05	HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE	PR
07/05	Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets	PR
06/05	Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology	PR
30/04	Halozyme to Report First Quarter 2026 Financial and Operating Results	PR
30/04	Halozyme Appoints Darren Snellgrove as Chief Financial Officer	PR
07/04	Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology	PR
19/03	Halozyme Therapeutics : ESG Key Data & Metrics (rev11 Halozyme ESG Key Data 2026 ISS Corporate comments Mar2026 version 1 for publication)	PU
12/03	Halozyme Appoints David Ramsay as Interim Chief Financial Officer	PR
06/03	U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma	PR
25/02	Halozyme to Participate in Upcoming Investor Conferences	PR
17/02	Halozyme Therapeutics: Q4 Earnings Snapshot	AQ
17/02	HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE	PR
10/02	Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results	PR